In December 2020, which company has partnered with Russia’s Gamaleya Research Institute, (RDIF) and R-Pharm to assess the safety and immunogenicity of a combination of their respective adenovirus-vector vaccines AZD1222 and Sputnik V?
In December 2020, which company has partnered with Russia’s Gamaleya Research Institute, (RDIF) and R-Pharm to assess the safety and immunogenicity of a combination of their respective adenovirus-vector vaccines AZD1222 and Sputnik V? Correct Answer AstraZeneca
The correct answer is AstraZeneca.
- AstraZeneca plc has partnered with Russia’s Gamaleya Research Institute, Russian Direct Investment Fund (RDIF) and R-Pharm.
- It will conduct a clinical trial to assess the safety and immunogenicity of a combination of their respective adenovirus-vector vaccines AZD1222 and Sputnik V.
- The trial will begin enrolling adults aged 18 and older.